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Background:  Tobacco  withdrawal  symptoms  may  be confounded  with  attention-deﬁcit/hyperactivity
disorder  (ADHD)  symptoms  among  smokers  with  ADHD.
Objective:  (1)  To  assess  overlap  between  ADHD  symptoms  and  tobacco/nicotine  withdrawal  symptoms
and  craving;  (2)  to assess  the  relationship  between  craving  or  withdrawal  symptoms  and  the  effect
of  osmotic-release  oral  system  methylphenidate  (OROS-MPH)  on  ADHD  symptoms;  (3)  to  assess  the
association  of  ADHD  symptoms,  craving,  and  withdrawal  symptoms  with  abstinence.
Methods:  Secondary  analysis  of  a  randomized,  placebo  controlled  smoking  cessation  trial  assessing  the
efﬁcacy of OROS-MPH  taken  in  addition  to  nicotine  patch  among  individuals  with  ADHD.  ADHD  symp-
toms,  withdrawal  symptoms,  and  craving  were  assessed  at baseline  and  2, 4  and  6  weeks  after  a  target
quit  day.
Results:  Withdrawal  symptoms  and  craving  showed  limited  and  modest  overlap  with  ADHD  symptoms
prior  to  abstinence  but  more  extensive  and  stronger  correlation  after  quit  day.  Compared  to  placebo,
OROS-MPH  reduced  ADHD  symptoms;  this  effect  was attenuated  by  controlling  for withdrawal  symp-
toms,  but  not  by craving.  Craving,  but not  ADHD  symptoms  and  withdrawal  symptoms,  was  associated
with  abstinence  during  the trial.
Conclusion:  When  treating  smokers  with  ADHD  (1)  craving,  rather  than  tobacco  withdrawal  symptoms
or  ADHD  symptoms  may  be the  more  effective  therapeutic  smoking  cessation  targets;  (2) careful  distinc-
tion of  craving,  withdrawal  symptoms,  and ADHD  symptoms  when  assessing  withdrawal  phenomena  is
needed.
. Introduction
Tobacco smoking, nicotine/tobacco dependence and attention-
eﬁcit/hyperactivity disorder (ADHD) frequently co-occur. Persons
ith ADHD are more likely to become regular smokers (Pomerleau
t al., 1995; Tercyak et al., 2002), begin smoking earlier, smoke
ore heavily (Kollins et al., 2005; Lambert and Hartsough, 2000),
nd may  experience greater difﬁculty when trying to stop smok-
ng (Humﬂeet et al., 2005; Covey et al., 2008) compared to persons
ithout ADHD. Nicotine ameliorates inattentiveness and problems
n response inhibition (Conners et al., 1996; Levin et al., 1996; Potter
nd Newhouse, 2004; Poltavski and Petros, 2006), which are core
ymptoms of ADHD. Nicotine can reduce the demonstrated deﬁcits
n dopaminergic function associated with ADHD (Volkow et al.,
∗ Corresponding author. Tel.: +33 1 42 16 16 78; fax: +33 1 42 16 16 88.
E-mail address: ivan.berlin@psl.aphp.fr (I. Berlin).
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2007) suggesting a “self-medication” rationale for greater tobacco
use among persons with ADHD (Gray and Upadhyaya, 2009).
The increased recognition that tobacco use and nicotine depen-
dence are highly prevalent among persons with ADHD (Gray
and Upadhyaya, 2009) has spurred investigations into details of
the relationship between those disorders, such as the associ-
ation between their symptom proﬁles. The core symptoms of
ADHD (inattention, hyperactivity, and impulsiveness; APA, 2000)
are conceptually and clinically similar to symptoms of nicotine
withdrawal, such as difﬁculty concentrating, restlessness, and
impatience (APA, 2000). A study of adolescent smokers that exam-
ined correlations during the non-abstinence phase of a smoking
cessation treatment found signiﬁcant correlations among sev-
eral of the ADHD and the nicotine withdrawal symptoms (Gray
et al., 2010). A 12-day abstinence trial conducted with adult, non-
Open access under CC BY-NC-ND license.treatment seeking smokers, on the other hand, observed that
withdrawal symptoms, which were experienced more severely by
smokers with than without ADHD, were unrelated to changes in
ADHD symptoms (McClernon et al., 2011).
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To clarify relationships among smoking-related (i.e., withdrawal
ymptoms and craving) and ADHD-related symptoms, as well as
heir relevance to the efﬁcacy of smoking cessation treatment for
mokers with ADHD, we conducted secondary analyses of data from
 trial of osmotic-release oral system methylphenidate (OROS-
PH) for smokers with ADHD (Winhusen et al., 2010). The parent
rial was a randomized, placebo controlled trial that evaluated if
ROS-MPH to treat ADHD, combined with smoking cessation treat-
ent, increases smoking abstinence. The main results showed that
ROS-MPH reduced ADHD symptoms but did not improve smoking
bstinence rate (Winhusen et al., 2010).
Our objectives in the current analysis were: (1) to assess over-
ap between ADHD symptoms and nicotine withdrawal symptoms
nd craving; (2) to assess the relationship between craving or with-
rawal symptoms and the OROS-MPH effect on ADHD symptoms;
3) to assess the association of ADHD symptoms, craving, and with-
rawal symptoms with abstinence. Findings from these analyses
ould impact clinical decisions regarding the manner, timing, and
ype of smoking cessation treatment when the smoker trying to
uit also suffers from ADHD.
. Methods
.1. Design of the parent OROS-MPH trial
Brieﬂy, this was  a randomized, double-blind, placebo-controlled trial assessing
he efﬁcacy of OROS-MPH compared to placebo for increasing smoking cessation rate
mong adult smokers with ADHD when added to nicotine patch and counseling. The
tudy design consisted of an 11-week treatment phase with a four-week pre-quit
hase and seven weeks of a planned abstinence period. All participants received a
horough explanation of the study from the investigators and signed an informed
onsent form. The trial was  conducted at six sites (Cambridge, MA;  Columbus, OH;
ew  York City, NY (2 sites); Portland, OR; Rochester, MN)  and approved by the
nstitutional Review Board at individual participating sites.
Participants were given 21 mg/24 h nicotine patches from the target quit day
day 27) through week 11, received 14 mg/24 h patches for study weeks 12 and 13,
nd  7 mg/24 h patches for study week 14. Participants were randomized to OROS-
PH  or matching placebo in a 1:1 ratio, with stratiﬁcation by site, by a centralized,
omputerized system. For OROS-MPH the starting dose of 18 mg/day was escalated
uring the ﬁrst two study weeks to a maximum of 72 mg/day or to the highest dose
olerated. Study participants received $25 ($15 at one site) per research visit; at
he  end-of-treatment visit (week 11) participants received an additional $25. More
etails of the study protocol, methods, and procedures are provided in the main
utcome paper (Winhusen et al., 2010).
.2. Participants
Eligible participants were adults with ADHD who  smoked at least 10 cigarettes
er  day, had an expired air carbon monoxide (CO) level ≥ 8 ppm, and smoked
igarettes regularly for at least 3 months prior to inclusion, wished to quit smoking,
ere in good physical health as determined by a medical history, electrocardio-
ram, vital signs and fulﬁlled DSM-IV criteria for ADHD as assessed by the Adult
linical Diagnostic Scale version 1.2 (Adler and Cohen, 2004). The use of the parent
tudy’s data and analysis was  approved by the IRB of the New York State Psychiatric
nstitute, Columbia University.
.3. Measures
The ADHD Rating Scale (ADHD-RS; DuPaul et al., 1998; Adler and Cohen, 2004)
as used to assess DSM-IV ADHD symptoms. This instrument contains 18 individual
tems, 9 each reﬂecting inattention and hyperactivity/impulsivity. Each item is rated
n a 4-point scale (never or rarely: 0, sometimes: 1, often: 2, very often: 4). The
otal score can range from 0 to 54, the maximum score for both inattention and
yperactivity/impulsivity subscales is 27. Cronbach’s  ˛ for the ADHD-RS at baseline
as 0.86 in this study. ADHD symptoms were assessed at baseline (three to four
eeks before a target quit date), and at weeks 2, 4, and 6 after the target quit date.
Tobacco withdrawal symptoms and craving were assessed with the Minnesota
ithdrawal Symptom Scale (MNWS) (Hughes and Hatsukami, 1986) at baseline
nd at weeks 2, 4, and 6 after quit day. Although DSM-IV does not include crav-
ng  for smoking as a withdrawal symptom, we  examined the “desire to smoke”
tem  in the MNWS,  referred to in the literature and in this paper as “craving.” Crav-
ng was  assessed separately from the seven other MNWS  items (anger/irritability,
nxiety/nervousness, difﬁculty concentrating, impatience/restlessness, hunger,
wakening at night, and depression). Cronbach’s  ˛ for the tobacco withdrawal symp-
oms at baseline was 0.78.endence 124 (2012) 268– 273 269
Smoking abstinence was assessed as 7-day point-prevalence abstinence as
reported at clinic visits on weeks 2, 4, and 6 after quit day by participants’ self-report
veriﬁed by expired carbon monoxide ≤8 parts per million. Continuous abstinence
(no slips or lapses from quit day) was treated as a time-varying variable in the mod-
els  only for completers (showed up at weeks 2, 4 and 6 after quit day), deﬁned
as  point-prevalence abstinence at week 2 for post-quit week 2, abstinence at both
weeks 2 and 4 for post quit week 4, and abstinence at weeks 2, 4, 6 for post-quit
week 6.
2.4. Data analysis
To assess the relationships between total and individual symptoms of ADHD,
withdrawal symptoms, and craving, we  used partial correlation coefﬁcients (Pear-
son’s r), controlling for age, gender, race/ethnicity, site, and treatment. We  adjusted
for  gender, based on prior research that showed its relationship with withdrawal
symptoms (McClernon et al., 2011), and for race/ethnicity (white vs. nonwhite)
based on prior evidence of its association with craving and abstinence (Covey et al.,
2010). We applied generalized linear models (GLM) to investigate the effects of
withdrawal symptoms and craving on total ADHD scores across the weeks of assess-
ment, and time (before quit day vs. post-quit day). We performed separate models
to  test the association of withdrawal symptoms and craving with ADHD symptoms.
Because a site effect has been demonstrated (Covey et al., 2011), it was tested as an
additional ﬁxed effect in the models. For the exploratory correlational analyses, p-
values ≤ 0.01 were considered as signiﬁcant to reduce likelihood of type 1 error due
to multiple testing. To investigate their associations with total ADHD scores dur-
ing  the post-quit period, the effect of treatment, smoking abstinence, withdrawal
symptoms and craving was  tested on a stepwise manner in the GLM models, con-
trolling for nicotine patch compliance and OROS-MPH (vs. placebo) compliance. In
order to test whether the associations between ADHD and withdrawal symptoms
or craving differed by treatment, the possible interactions among treatment and
withdrawal symptoms or craving were tested. The association of total ADHD scores,
withdrawal symptoms, and craving with smoking abstinence was  also investigated
using GLM models. The GLM methodology was able to handle within-subject corre-
lations (Little and Rubin, 1987; Diggle et al., 2004). PROC Glimmix in SAS (SAS 9.2)
was  used to conduct the analyses.
3. Results
3.1. Characteristics of the sample
The total sample consisted of 255 smokers with ADHD. The
mean age was 37. 8 years (SD = 10, range: 19–56); 56.5% of the
sample was male, 34.1% were married, 22.4% were divorced or sep-
arated and 43.9% were single; 79.2% were non-Hispanic Whites,
13.7% African Americans and 6.3% Hispanics. The mean age at start-
ing smoking was 13.8 years (SD = 3, range: 5–27). The mean number
of cigarettes smoked per day was  20.2 (SD = 10, range: 10–60). The
mean number of years of education was 14.4 years (SD = 2.4, range:
6–24). One hundred eighty four smokers showed up at each post-
quit date visit (weeks 2, 4 and 6) and were deﬁned as a completer
sample; the distributions of demographic and smoking data in the
total and the completer samples were similar.
3.2. Associations between total ADHD symptoms, total tobacco
withdrawal symptoms, and craving at baseline and during the
post-quit period
Table 1 shows the means and standard deviations at baseline
and during the post-quit clinic visits for the total ADHD symptoms,
total nicotine withdrawal scores, and craving, and partial correla-
tion coefﬁcients between ADHD symptoms and the withdrawal and
craving measures. Mean scores on the three measures declined dur-
ing the study. The partial correlation coefﬁcients between ADHD
symptoms and withdrawal symptoms, signiﬁcant at all time points,
were substantially higher after the quit date than at baseline. For
craving, the correlations with ADHD symptoms were not signiﬁ-
cant at baseline, but increased to statistical signiﬁcance at weeks
2–6 after quit day.A Glimmix model on ADHD symptoms did not show signiﬁ-
cant effects of age, gender, or race/ethnicity (all p-values > 0.10).
The association between withdrawal symptoms and ADHD symp-
toms after quit day was signiﬁcantly stronger than before the
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Table 1
Two-sided correlation coefﬁcients between ADHD-RS scores and nicotine/tobacco withdrawal symptoms, craving, at baseline and during post-quit periodsa (N = 245).
ADHD Withdrawal symptoms Craving
Mean (SD) Baseline Week 2
post quit
Week 4
post quit
Week 6
post quit
Baseline Week 2
post quit
Week 4
post quit
Week 6
post quit
Mean (SD) 12.04 (5.49) 9.14 (5.71) 8.21 (5.49) 7.48 (5.32) 3.23 (0.67) 2.09 (1.27) 1.87 (1.25) 1.81 (1.26)
Baseline 36.36 (7.29) 0.23* 0.08
Week  2 post quit 22.85 (12.46) 0.47* 0.26*
Week 4 post quit 22.19 (12.76) 0.47* 0.34*
Week 6 post quit 21.35 (12.56) 0.45* 0.25*
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(DHD-RS: attention-deﬁcit/hyperactivity disorder rating scale.
a Adjusted for age, gender, race/ethnicity, site and treatment group.
* p < 0.01 (two-sided).
uit day (  ˇ = 0.46, s.e. = 0.11, p < 0.0001). As in the correlational
nalysis, the Glimmix model showed a signiﬁcant association
etween ADHD-RS scores and withdrawal symptoms at base-
ine (  ˇ = 0.36, s.e. = 0.09, p < 0.0001) and after quit day (  ˇ = 0.82,
.e. = 0.07, p < 0.0001). Also consistent with the correlational analy-
is, there was no association between craving and ADHD symptoms
t baseline (  ˇ = 0.34, s.e. = 0.77, p = 0.66) but a signiﬁcant association
ccurred after quit day (  ˇ = 1.74, s.e. = 0.32, p < 0.0001). However,
he effect of the time by craving interaction term was  not signiﬁcant
 ˇ = 1.40, s.e. = 0.81, p = 0.09).
.3. Associations between individual withdrawal symptoms,
ndividual ADHD symptoms, and craving
Table 2 explores the correlations of individual ADHD symptoms
ith craving and withdrawal symptoms at baseline and on the
econd week after quit day (similar correlations as seen at week
 were seen at weeks 4 and 6). At baseline, signiﬁcant correla-
ions of individual ADHD symptoms with craving as well as with
ndividual withdrawal symptoms were few and small in magni-
ude. These included correlations between impatience/restlessness
ith ﬁve of the hyperactivity/impulsivity symptoms, and between
nger/irritability with difﬁculty sustaining attention. At the sec-
nd week after quit day, more numerous signiﬁcant and stronger
orrelations between withdrawal and ADHD symptoms were evi-
ent. These included signiﬁcant correlations between individual
ithdrawal symptoms and several ADHD items, i.e., all 18 ADHD
ymptoms with impatience/restlessness, 17 with difﬁculty concen-
rating, 16 with anxiety/nervousness, 14 with anger/irritability, 10
ith depression, and 5 with awakening at night. Hunger, a with-
rawal symptom not putatively associated with ADHD, did not
how a correlation with any ADHD symptom at any time during
he trial. No correlations between craving and any of the ADHD
ymptoms were observed at baseline; after quit day, a number of
igniﬁcant correlations between craving and several ADHD symp-
oms (5 inattentive and 1 hyperactivity symptoms) were observed.
.4. Withdrawal symptoms, craving, and treatment effects on
DHD symptoms during the post-quit period
The basic Glimmix model on ADHD symptoms (Table 3) dur-
ng the post-quit period showed a signiﬁcant treatment effect,
.e., ADHD scores decreased more on OROS-MPH than on placebo
ˇ = −6.05, s.e. = 1.38, p < 0.001). Abstinence status was  not asso-
iated with ADHD scores. Addition of withdrawal symptoms to
he basic model showed that both withdrawal symptoms and
reatment were signiﬁcantly associated with ADHD symptoms. In
rder to test whether the associations between ADHD and with-
rawal symptoms or craving differed by treatment, interaction
erms were entered in a Glimmix model. The only signiﬁcant inter-
ction was that between treatment and withdrawal symptoms
F(1, 378) = 7.12, p < 0.01). The association of withdrawal symptomswith ADHD scores was  signiﬁcantly stronger among patients on
OROS-MPH (  ˇ = 0.73, s.e. = 0.09, p < 0.0001) than among patients on
placebo (  ˇ = 0.38, s.e. = 0.13, p < 0.01).
Compared to OROS-MPH’s effect on ADHD scores in the absence
of withdrawal symptoms, inclusion of withdrawal symptoms was
associated with a decreased effect of OROS-MPH of about 26%
(= (−6.05 − (−4.50))/(−6.05)) on ADHD symptoms. Addition of
craving to the basic model continued to show a treatment effect on
ADHD symptoms (  ˇ = −5.98, s.e. = 1.36, p < 0.001), but no signiﬁcant
effect of craving (  ˇ = 0.35, s.e. = 0.30, p = 0.25) was observed.
3.5. Association of craving, withdrawal symptoms, and ADHD
symptoms with smoking abstinence
When craving, withdrawal symptoms, and ADHD symptoms
were included in a model that controlled for all potential
confounders and also for compliance with nicotine patch and
OROS-MPH/placebo treatment (Table 4), the only variable signiﬁ-
cantly and inversely associated with abstinence status was  craving
(  ˇ = −0.79, s.e. = 0.14, p < 0.0001). In a stepwise analysis, withdrawal
symptoms appeared to inﬂuence abstinence (ˇ = −0.08, s.e. = 0.03,
p = 0.0075), but when the effect of craving was controlled for,
the association of withdrawal symptoms with abstinence was  no
longer signiﬁcant (p = 0.97). The same results were observed for
continuous abstinence among completers (data not shown).
4. Discussion
This secondary analysis of data from a smoking cessation trial
demonstrated little correlation between ADHD symptoms and the
tobacco-related symptoms of craving and withdrawal before quit
day. However, during the post-quit period, signiﬁcant overlap
between ADHD symptoms and nicotine withdrawal symptoms, and
to a lesser extent, craving, became apparent. As reported earlier
(Winhusen et al., 2010), we observed an effect of OROS-MPH on
ADHD symptoms; in the present analysis we found that OROS-MPH
also reduced nicotine withdrawal symptoms, but not craving to
smoke. Conﬁrming results from a previous analysis (Covey et al.,
2010), craving, but not symptoms of ADHD or nicotine withdrawal
was  associated with abstinence. Assessment of compliance with
the treatment regimen (nicotine patch and OROS-MPH/placebo)
did not alter the observed relationships.
Studies have shown that smokers with ADHD experience with-
drawal symptoms more severely than do smokers without ADHD
(McClernon et al., 2008, 2011). The present study revealed signiﬁ-
cant correlations between ADHD and withdrawal symptoms during
the post-quit phase and, thus, the differences previously reported
between smokers with and without ADHD may reﬂect a confound-
ing between ADHD and withdrawal symptoms.
The present analysis has demonstrated that in adult smokers
with ADHD who  undergo smoking cessation treatment, nicotine
withdrawal symptoms and ADHD symptoms weakly overlap prior
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Table 2
Partial correlation coefﬁcients between individual ADHD symptoms, craving, and individual nicotine/tobacco withdrawal symptoms at baseline and week 2 post quit date.
N  = 245 (standard characters: baseline; italics: week 2 post-quit date)a.
Craving for
cigarettes
Depression Anger,
irritability
Anxiety,
nervousness
Difﬁculty
concentrating
Impatience,
restlessness
Hunger Awakening
at night
Inattention
Carelessness .02 .04 −.01 .07 .10 .08 −.005 .05
.19* .16 .19* .29* .47* .39* .03 .09
Difﬁculty sustaining attention .07 .07 .18* .12 .15 .15 .05 .04
.18  .22* .28* .30* .49* .43* .07 .16
Does  not listen .05 .04 .16 .11 .09 .10 .02 .02
.27* .21* .25* .30* .37* .42* .07 .12
No  follow through .04 .17 .14 .09 .05 .10 .08 .05
.21* .22* .23* .31* .44* .39* .09 .22*
Cannot organize .13 .07 −.03 −.08 .14 .04 .01 .06
.27* .18 .27* .28* .47* .38* .04 .16
Avoids/dislikes tasks requiring
sustained mental effort
.08 .14 .09 .07 .16 .15 .03 .07
.18  .17 .19* .24* .33* .34* .01 .15
Loses  important items .13 .04 .04 .09 .06 .13 .07 .08
.18  .20* .21* .31* .37* .34* .09 .22*
Easily distractible .06 .12 .07 .05 .06 .06 .08 .05
.16  .19* .22* .29* .40* .38* .03 .15
Forgetful in daily activities −.08 .06 .09 .001 .01 .08 .13 .002
.25* .23* .23* .27* .43* .39* .11 .13
Hyperactivity/impulsivity
Squirms and ﬁdgets .05 .11 .10 .07 .05 .19* .08 .06
.12  .11 .17 .24* .37* .36* .05 .15
Cannot stay seated .03 .06 .11 .16 .21* .24* .01 .10
.15  .20* .18 .31* .33* .35* .09 .22*
Runs/climbs excessively (restless) .07 .11 .13 .14 .13 .20* .12 .06
.23* .33* .33* .48* .37* .51* .14 .29*
Cannot play/work quietly −.1 .02 .10 .16 .13 .11 .06 −.01
.15 .23* .24* .36* .29* .34* .03 .08
On  the go, driven by a motor .001 .12 .13 .14 .21* .20* .08 .06
.15 .20* .18 .35* .31* .36* .11 .18
Talks  excessively .07 .03 .03 .001 .10 .04 .08 −.01
.04 .04  .06 .06 .10 .21* −.05 .08
Blurts  out answers .003 .003 .08 .03 .06 .06 −.01 .01
.16  .08 .20* .20* .25* .31* .04 .11
Cannot wait for turn .04 −.02 .08 .11 .15 .18* .05 .05
.14  .16 .23* .24* .36* .32* .06 .22*
Intrudes/interrupts others .1 .001 .04 .05 .07 .08 .03 −.08
.07  .08 .20* .17 .34* .29* .01 .13
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cDHD: attention-deﬁcit/hyperactivity disorder.
a Adjusted for age, gender, treatment group, site, and race/ethnicity.
* Bold numbers: p < 0.01, two-sided.o abstinence but may  be confounded during the post-quit period.
his ﬁnding implies the need for careful interpretation of nicotine
ithdrawal symptoms, both before and after the quit day, as the
eported symptoms may  be indicative of a co-occurring condition,
able 3
odel results of the association of ADHD symptoms score with treatment, nicotine wit
weeks  2, 4 and 6 post-quit).
Basic modela Basic model plus
withdrawal
Basic mo
OROS-MP
withdraw
 ˇ (s.e.)
Abstinence 0.28 (0.72) 0.41 (0.71) 0.42 (0.7
OROS-MPH (vs. placebo) −6.05** (1.38) −4.50* (1.26) −7.36** (1
Withdrawal symptoms 0.55** (0.07) 0.38** (0
Interaction between
OROS-MPH (vs. placebo) and
withdrawal
0.35* (0
Craving 
Interaction between
OROS-MPH (vs. placebo) and
craving
DHD: attention-deﬁcit/hyperactivity disorder.
a Adjusted for age, gender, race, treatment, week of assessment, site, nicotine patch co
ompliance, and baseline ADHD score.
* p < 0.001.
** p < 0.0001.such as ADHD. As suggested by Gray et al. (2010),  it may  be neces-
sary to develop speciﬁc measures that are not confounded by ADHD
symptoms to accurately assess smoking cessation progress in the
presence of ADHD. Our two-fold ﬁnding of increased correlation
hdrawal symptoms, craving to smoke and abstinence status after target quit date
del plus interaction
H (vs. placebo) and
al
Basic model plus
craving
Basic model plus interaction
OROS-MPH (vs. placebo) and
craving
1) 0.14 (0.76) 0.13 (0.76)
.65) −5.98** (1.36) −5.40* (1.76)
.09)
.13)
0.35 (0.30) 0.50 (0.41)
−0.30 (0.58)
mpliance, osmotic-release oral system methylphenidate (OROS-MPH) vs. placebo
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Table 4
Association of ADHD symptoms score, treatment, nicotine withdrawal symptoms and craving to smoke with smoking abstinence after target quit date (weeks 2, 4 and 6
post-quit).
Basic modela Basic model plus withdrawal
symptoms
Basic model plus withdrawal
and craving
 ˇ (s.e.)
Total ADHD symptoms −0.01 (0.01) 0.01 (0.01) 0.004 (0.01)
OROS-MPH (vs. placebo) 0.17 (0.34) 0.02 (0.34) 0.08 (0.34)
Withdrawal symptoms −0.08 (0.03)* −0.002 (0.04)
Craving −0.79 (0.14)**
ADHD: attention-deﬁcit/hyperactivity disorder.
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iAdjusted for age, gender, race, treatment, week of assessment, site, nicotine patch
* p < 0.01.
** p < 0.0001.
etween withdrawal symptoms and ADHD symptoms following
uit day, and the lack of predictive effect of withdrawal symptoms
n abstinence (upon controlling for craving) contrasts with ﬁndings
y McClernon et al. (2011).  These authors observed that withdrawal
ymptoms were associated with abstinence, and this association
as unrelated to ADHD symptoms. The difference in observa-
ions could result from methodological differences between the
2-day trial (McClernon et al., 2011) and our parent OROS-MPH
rial (Winhusen et al., 2010): (1) the post-quit period was  7-weeks
n our study and only 12 days in the study by McClernon et al.,
2) study participants in our study had entered the trial seeking
o stop smoking whereas only smokers who were not planning to
top smoking entered the 12-day trial, (3) a speciﬁc association of
raving with withdrawal symptoms and their combined associa-
ion with abstinence was not evaluated in the 12-day trial, (4) the
ithdrawal measure used by McClernon et al. (2011),  the Shiffman-
arvik Withdrawal Questionnaire (SJWQ), described as a “32-item
easure of craving,” may  have captured elements of the addic-
ion process that were better reﬂective of craving than the items
ncluded in the MNWS.
There was a signiﬁcant interaction effect of treatment and
ithdrawal symptoms on ADHD symptoms but no treatment by
raving interaction effect was observed. Thus, ADHD symptoms
ere associated with both OROS-MPH and withdrawal symptoms
ut not with craving. The irregular association of craving with
DHD symptoms (no craving-ADHD symptoms association at base-
ine, inconsistent association after quit day) may  simply reﬂect the
arallel evolution of craving with withdrawal symptoms. The asso-
iation between withdrawal symptoms and ADHD symptoms was
tronger with OROS-MPH than with placebo, which likely reﬂects
educed variance from OROS-MPH acting on similar ADHD and
ithdrawal symptoms.
Amelioration of the ADHD and withdrawal symptoms with
ROS-MPH did not result in successful smoking cessation among
he participants in the present study (Covey et al., 2010; Winhusen
t al., 2010); rather, it was reduction in craving to smoke, which was
rregularly associated with both withdrawal symptoms and ADHD
ymptoms (as shown in Tables 1 and 2) that facilitated smoking ces-
ation. Withdrawal symptoms showed signiﬁcant correlation with
DHD symptoms and abstinence but inclusion of craving nulliﬁed
he withdrawal symptoms – abstinence association. Withdrawal
ymptoms may  be uncertain predictors of abstinence because their
ssociation with smoking abstinence is confounded by craving. This
ay  explain also why ADHD symptoms, which do not tap craving,
ere not associated with abstinence status.
The limited correlation between craving and ADHD symptoms,
long with the demonstrated inﬂuence of craving on abstinence
Covey et al., 2010), may  help to explain why, despite its record
s an efﬁcacious medication for alleviating symptoms of ADHD
McBurnett and Starr, 2011), OROS-MPH did not increase smok-
ng cessation rates in the present sample of smokers with ADHDliance, and osmotic-release oral system methylphenidate (vs. placebo) compliance.
(Winhusen et al., 2010). Nicotine has been found to reduce ADHD
symptoms (Gehricke et al., 2009) and ADHD medications reduce
nicotine withdrawal symptoms in smokers with ADHD (Gehricke
et al., 2011). However, ADHD medications do not seem to reduce
craving to smoke (Gehricke et al., 2011), a core predictor of success-
ful smoking cessation (Dawkins et al., 2009; Berlin et al., 2011). The
lack of a signiﬁcant OROS-MPH effect on craving may not general-
ize to the effects that would be observed with immediate release
methylphenidate (IR MPH). Speciﬁcally, laboratory ﬁndings have
shown that IR MPH  signiﬁcantly increases smoking in adult smok-
ers without ADHD who  are not trying to quit smoking (Rush et al.,
2005; Vansickel et al., 2007) and, thus, might serve to increase
craving. Thus, medications acting on craving may  be a promising
smoking cessation for smokers with ADHD.
A primary strength of the present study is the evaluation of
smokers with ADHD who  wanted to quit smoking and were studied
prior to and after their quit attempt, which more closely reﬂects
the clinical setting compared to the studies by Gray et al. (2010)
and McClernon et al. (2011) that sought to evaluate the relation-
ship between nicotine withdrawal and ADHD. However, this was
a secondary, post hoc analysis of a randomized therapeutic trial;
thus, further studies speciﬁcally planned for investigating the over-
lap between ADHD and nicotine withdrawal symptoms are needed
to conﬁrm the current ﬁndings. Similarly, prospective studies are
needed to conﬁrm the lack of association between ADHD symp-
toms and smoking abstinence and the potential predictive role of
craving in successful quitting in this speciﬁc population. The gen-
eralizability of the ﬁndings warrant caution because of the evident
selection bias characterizing clinical therapeutic trials.
In conclusion, among smokers with ADHD, ADHD symptoms
and nicotine withdrawal symptoms may  overlap, in particular,
after quitting smoking. Craving to smoke but not ADHD or nico-
tine withdrawal symptoms is associated with smoking abstinence.
Reduction of craving may  help smokers with ADHD quit.
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